Literature DB >> 18024817

Decreased retinal vein diameter after intravitreal triamcinolone for retinal vein occlusions.

Jost B Jonas1, Florian Rensch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024817      PMCID: PMC2095540          DOI: 10.1136/bjo.2007.116558

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.

Authors:  Paul B Greenberg; Adam Martidis; Adam H Rogers; Jay S Duker; Elias Reichel
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion.

Authors:  Carl H Park; Glenn J Jaffe; Sharon Fekrat
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

3.  Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion.

Authors:  Michael S Ip; K S Kumar
Journal:  Arch Ophthalmol       Date:  2002-09

4.  Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion.

Authors:  Osman Cekiç; Stanley Chang; Joseph J Tseng; Gaetano R Barile; Lucian V Del Priore; Harold Weissman; William M Schiff; Michael D Ober
Journal:  Retina       Date:  2005 Oct-Nov       Impact factor: 4.256

5.  Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert F Degenring
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-13       Impact factor: 3.117

  5 in total
  1 in total

1.  Effects of triamcinolone acetonide on vessels of the posterior segment of the eye.

Authors:  Fatemeh Valamanesh; Marianne Berdugo; Florian Sennlaub; Michèle Savoldelli; Cyndie Goumeaux; Marianne Houssier; Jean-Claude Jeanny; Alicia Torriglia; Francine Behar-Cohen
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.